deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02529813

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies

Sponsor: M.D. Anderson Cancer Center

Conditions Acute Biphenotypic Leukemia Acute Lymphoblastic Leukemia Blasts 5 Percent or More of Bone Marrow Nucleated Cells CD19 Positive Minimal Residual Disease Non-Hodgkin Lymphoma Small Lymphocytic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage IV Chronic Lymphocytic Leukemia
Interventions Cyclophosphamide Fludarabine Phosphate Laboratory Biomarker Analysis Tisagenlecleucel
Updated 13 times since 2017 Last updated: Jun 29, 2022 Started: Dec 16, 2015 Primary completion: Nov 8, 2021 Completion: Nov 8, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Acute Biphenotypic Leukemia and Acute Lymphoblastic Leukemia and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Dec 2021 — Jul 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE1

▶ Show 8 earlier versions

  1. Aug 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  4. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  5. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  6. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  7. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE1

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
  • Ziopharm Oncology
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations